Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Acquisitions & Divestments (2018 - 2021)

Historic Change in Acquisitions & Divestments for Iradimed (IRMD) over the last 4 years, with Q4 2021 value amounting to $440000.0.

  • Iradimed's Change in Acquisitions & Divestments rose 898.78% to $440000.0 in Q4 2021 from the same period last year, while for Dec 2022 it was $440000.0, marking a year-over-year decrease of 4784.97%. This contributed to the annual value of $500000.0 for FY2022, which is 6402.88% down from last year.
  • According to the latest figures from Q4 2021, Iradimed's Change in Acquisitions & Divestments is $440000.0, which was up 898.78% from $403715.0 recorded in Q4 2020.
  • Iradimed's Change in Acquisitions & Divestments' 5-year high stood at $1.5 million during Q3 2019, with a 5-year trough of $400000.0 in Q2 2019.
  • Over the past 4 years, Iradimed's median Change in Acquisitions & Divestments value was $775000.0 (recorded in 2018), while the average stood at $825714.4.
  • Per our database at Business Quant, Iradimed's Change in Acquisitions & Divestments surged by 6355.56% in 2019 and then tumbled by 6534.64% in 2020.
  • Over the past 4 years, Iradimed's Change in Acquisitions & Divestments (Quarter) stood at $1.2 million in 2018, then fell by 0.85% to $1.2 million in 2019, then plummeted by 65.35% to $403715.0 in 2020, then rose by 8.99% to $440000.0 in 2021.
  • Its Change in Acquisitions & Divestments was $440000.0 in Q4 2021, compared to $403715.0 in Q4 2020 and $1.2 million in Q4 2019.